{
  "docId": "019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "docSlug": "9e6f9592721adb102aeba3d640e068ca",
  "documentTitle": "Immix Biopharma | Investor Presentation Deck | 64 slides",
  "authorId": "immix-biopharma",
  "authorName": "Immix Biopharma",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 64,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 25,
  "notes": "The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-ab6f-74fc-ae2c-88fa7eed31fd/33",
  "deckHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd",
  "deckJsonHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd.json",
  "deckAnchorHref": "/decks/019de076-ab6f-74fc-ae2c-88fa7eed31fd#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.94,
        "x": 0.03,
        "y": 0.85
      },
      "kind": "callout",
      "text": "14,982 patient annual incidence",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a961efb-9145-4298-8369-38864e14e7b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Birtamimab Source: Gertz MA et al. First-in-Human Phase I/II Study of NEOD001... [full citation text]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eeb275da-398e-4d5e-bd9f-3bf7241ea538",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.94,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "table",
      "text": "Comparison table of NXC-201 vs Darzalex, Investigator's Choice, Caelum, and Birtamimab across various clinical metrics.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5714ec04-65da-4d4a-baad-949f34e35bb4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "NXC-201 Clinical Results Demonstrate Potential for Best-in-Class Efficacy & Safety in AL (light chain) Amyloidosis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bd2173d7-eab7-4c9d-8dd0-dc377b3724fe",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "dce88895-f937-436f-9c7a-663cf7161af1",
      "evidence": "Comparative table of clinical efficacy metrics across multiple therapeutic agents.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 36,
      "from": 19,
      "beatId": "ab2925a6-fd2e-488b-b430-e58988921ddc",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "Slides 19-36 provide clinical data and results for NXC-201",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}